Portfolio Strategy: How To Drive Deal Value With Drug Target Analysis

BI
Buchanan Ingersoll & Rooney PC

Contributor

With 450 attorneys and government relations professionals across 15 offices, Buchanan Ingersoll & Rooney provides progressive legal, business, regulatory and government relations advice to protect, defend and advance our clients’ businesses. We service a wide range of clients, with deep experience in the finance, energy, healthcare and life sciences industries.
For life sciences companies and investors, determining the value of a single product or an entire product portfolio is a crucial first step in asset investment, acquisition, or divestiture.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

For life sciences companies and investors, determining the value of a single product or an entire product portfolio is a crucial first step in asset investment, acquisition, or divestiture.

This requires a 360° analysis, looking at everything from a product's intellectual property (IP) and U.S. Food and Drug Administration (FDA) regulatory exclusivity protection to the broader market landscape, competition and potential FDA regulatory hurdles.

Our Guide to Drug Target Analysis provides insight on:

  • What is Drug Target Analysis?
  • Managing patent portfolios
  • Navigating complex FDA regulatory requirements
  • Driving Deal Value

This tool should be an essential part of every life sciences company's drug program, enabling them to make informed decisions that drive deal value in their favor.

Download your Guide to Drug Target Analysis

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More